Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
Jan 2019
Historique:
entrez: 24 1 2019
pubmed: 24 1 2019
medline: 10 7 2020
Statut: ppublish

Résumé

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.

Identifiants

pubmed: 30670142
doi: 10.2807/1560-7917.ES.2019.24.3.1800698
pmc: PMC6344841
doi:

Substances chimiques

Antiviral Agents 0
Dibenzothiepins 0
Morpholines 0
Oxazines 0
Pyridines 0
Pyridones 0
Thiepins 0
Triazines 0
baloxavir 4G86Y4JT3F
Endonucleases EC 3.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Antivir Ther. 2007;12(4 Pt B):603-16
pubmed: 17944268
Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74
pubmed: 23061103
Influenza Other Respir Viruses. 2017 May;11(3):240-246
pubmed: 28146320
Sci Rep. 2018 Jun 25;8(1):9633
pubmed: 29941893
N Engl J Med. 2018 Sep 6;379(10):913-923
pubmed: 30184455
Front Microbiol. 2018 Dec 06;9:3026
pubmed: 30574137

Auteurs

Emi Takashita (E)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Chiharu Kawakami (C)

Yokohama City Institute of Public Health, Kanagawa, Japan.

Hiroko Morita (H)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Rie Ogawa (R)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Seiichiro Fujisaki (S)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Masayuki Shirakura (M)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Hideka Miura (H)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Kazuya Nakamura (K)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Noriko Kishida (N)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Tomoko Kuwahara (T)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Keiko Mitamura (K)

Eiju General Hospital, Tokyo, Japan.

Takashi Abe (T)

Abe Children's Clinic, Kanagawa, Japan.

Masataka Ichikawa (M)

Ichikawa Children's Clinic, Kanagawa, Japan.

Masahiko Yamazaki (M)

Zama Children's Clinic, Kanagawa, Japan.

Shinji Watanabe (S)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Takato Odagiri (T)

Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
The members of the group are listed at the end of the article.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH